In this issue:
- Hormone therapy + post operative radiotherapy for recurrent prostate cancer
- SABRT for primary kidney cancer
- Trans-Tasman outcomes in advanced ccRCC
- Adverse events with adjuvant pembrolizumab for RCC
- ICI-based therapies for sarcomatoid RCC
- Pembrolizumab-lenvatinib vs axitinib regimens in metastatic ccRCC
- Alternative GAMMA regimen in relapsed germ cell tumours
- Prior primary tumour resection in metastatic RCC
- Perioperative apalutamide in high-risk localised prostate cancer
- Transdermal oestradiol patches in locally advanced prostate cancer
Please login below to download this issue (PDF)